Home › Compare › ELLKF vs ABBV
ELLKF yields 35.31% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 4
Combined, ELLKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ELLKF + ABBV for your $10,000?
Ellaktor S.A., through its subsidiaries, engages in the construction and quarrying, wind energy, concession, environment, and real estate development businesses in Greece, other European countries, Gulf countries, the Americas, and Australia. The company operates through five segments: Construction, Concessions, Renewable Energy Sources (RES), Environment, and Real estate Development. It constructs bridges, motorways, metro projects, biological treatment plants, natural gas pipelines, refineries, shopping centers, casinos, tourist and hotel units, cultural centers, hospitals, airports, Olympic and athletic complexes, railway projects, tunnels, dams, port projects, energy production stations, electromechanical projects, etc.; and logistics, office, residential, industrial, and educational buildings. The company is also involved in the waste management and energy production, which include design, construction, and operation of waste treatment plant, as well as offers alternative fuel production and biomass exploitation projects. In addition, it develops, constructs, and operates wind farms; provides real estate development and services, which consists of retail parks, entertainment centers, residential complexes, exhibition centers, and offices and mixed use buildings, as well as offers consultancy and services to third parties. The company was formerly known as ELLINIKI TECHNODOMIKI TEB SA and changed its name to Ellaktor S.A. in 2008. The company is headquartered in Athens, Greece.
Full ELLKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.